	US 12,252,516 B2
	Mucoadhesive microorganism
Lothar Steidler, Lokeren (BE); and Klaas Vandenbroucke, De Pinte (BE)
Assigned to INTREXON ACTOBIOTICS N.V., Zwijnaarde (BE)
Filed by INTREXON ACTOBIOTICS N.V., Zwijnaarde (BE)
Filed on Jun. 6, 2022, as Appl. No. 17/832,745.
Application 17/026,379 is a division of application No. 16/331,660, granted, now 10,808,014, issued on Oct. 20, 2020, previously published as PCT/IB2017/055470, filed on Sep. 11, 2017.
Application 17/832,745 is a continuation of application No. 17/026,379, filed on Sep. 21, 2020, granted, now 11,384,123.
Claims priority of provisional application 62/394,024, filed on Sep. 13, 2016.
Prior Publication US 2023/0013523 A1, Jan. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/335 (2006.01); A61K 35/74 (2015.01); A61K 35/741 (2015.01); A61P 3/10 (2006.01); C07K 14/435 (2006.01); C07K 14/575 (2006.01); C12N 9/88 (2006.01); A61K 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/335 (2013.01) [A61K 35/74 (2013.01); A61K 35/741 (2013.01); A61P 3/10 (2018.01); C07K 14/435 (2013.01); C07K 14/575 (2013.01); C12N 9/88 (2013.01); A61K 2035/115 (2013.01); A61K 39/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/036 (2013.01)]

22 Claims

1. A recombinant lactic acid bacterium (LAB) for treating a disease in a subject in need thereof comprising:

(i) a first exogenous nucleic acid encoding a fusion protein; and

(ii) a second exogenous nucleic acid encoding a therapeutic polypeptide, wherein said fusion protein comprises:

(a) an N-terminal trefoil factor (TFF) polypeptide; and

(b) a C-terminal cell adherence polypeptide comprising a cell-wall anchoring domain,

and wherein said therapeutic polypeptide, upon administering said recombinant LAB to said subject, is capable of being delivered to a mucosal tissue of said subject to treat said disease.